title: Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia.
authors.affiliation: The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
authors.forename: M
authors.initials: M
authors.lastname: Dungarwalla
authors.forename: A
authors.initials: A
authors.lastname: Field-Smith
authors.forename: C
authors.initials: C
authors.lastname: Jameson
authors.forename: U
authors.initials: U
authors.lastname: Riley
authors.forename: A
authors.initials: A
authors.lastname: Chapman
authors.forename: C B
authors.initials: CB
authors.lastname: Bunker
authors.forename: C E
authors.initials: CE
authors.lastname: Dearden
authors.forename: E
authors.initials: E
authors.lastname: Matutes
mesh_terms: D000361:Agammaglobulinemia / Q000150:complications; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D016867:Immunocompromised Host; D007167:Immunotherapy / Q000009:adverse effects; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D008297:Male; D009165:Mycobacterium Infections, Nontuberculous / Q000150:complications* / Q000175:diagnosis / Q000382:microbiology; D016926:Mycobacterium chelonae / Q000302:isolation & purification*; D009894:Opportunistic Infections / Q000150:complications* / Q000175:diagnosis / Q000382:microbiology; D017192:Skin Diseases, Bacterial / Q000150:complications* / Q000175:diagnosis / Q000382:microbiology; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine